|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.10.25 - 22:09
|
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 (GlobeNewswire EN)
|
|
|
REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. BDC-4182 preclinical data supports this approach....
|
|
|
|
|
|
|
14.08.25 - 22:06
|
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
|
|
|
REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline,” said Willie Quinn, President and Chief Executive Officer. “We are now conducting a Phase 1 dose-escalation study for patients with gastric and gastroesophageal cancer in Australia, and will expand to other countries in the second half of 2025. We look forward to presenting initial data in the first half of 2026. We also continue to seek a partner for further development of our dectin-2 agonist antibody BDC-3042, which demonstrated activity in lung cancer patients in the form of a partial response (PR) at the highest dose tested. Patients at the highest doses also had a strong imm...
|
|
|
09.06.25 - 08:18
|
XFRA: 6LP0,ITH0,PXL: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
BOLT BIOTHE.NEW DL-,00001 6LP0 US0977022039 BAW/UFN
NEKTAR THERAP. NEW O.N. ITH0 US6402683063 BAW/UFN
PIXELWORKS INC. DL-,001 PXL US72581M4042 BAW/UFN...
|
|
|
|
|
06.06.25 - 16:48
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
US0977021049 Bolt Biotherapeutics Inc. 06.06.2025 US0977022039 Bolt Biotherapeutics Inc. 09.06.2025 Tausch 20:1
SE0018041097 Spotr Group AB 06.06.2025 SE0025166416 Spotr Group AB 09.06.2025 Tausch 250:1
US00808Y4061 Aethlon Medical Inc. 06.06.2025 US00808Y5050 Aethlon Medical Inc. 09.06.2025 Tausch 8:1
US72581M3051 Pixelworks Inc. 06.06.2025 US72581M4042 Pixelworks Inc. 09.06.2025 Tausch 12:1
US6402681083 Nektar Therapeutics 06.06.2025 US6402683063 Nektar Therapeutics 09.06.2025 Tausch 15:1
KYG1146Y1017 Beone Medicines Ltd. 06.06.2025 CH1391448177 BeOne Medicines AG 09.06.2025 Tausch 1:1...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
